While existing therapeutic interventions do indicate some pathway biases in disease pathogenesis, such as TNF inhibitors in rheumatoid arthritis or IL17 inhibitors in psoriasis, our data demonstrate that orally administered EDP1867 is effective in murine models of Th1, Th2 and Th17 inflammation. This evidence concerns the gene TNF and psoriasis.